Reyataz and Alpha 1 foetoprotein abnormal - a phase IV clinical study of FDA data

Summary:

Alpha 1 foetoprotein abnormal is reported as a side effect among people who take Reyataz (atazanavir sulfate), especially for people who are female, 30-39 old, have been taking the drug for < 1 month also take Norvir, and have Ill-defined disorder.

The phase IV clinical study analyzes which people have Alpha 1 foetoprotein abnormal when taking Reyataz. It is created by eHealthMe based on reports of 11,228 people who have side effects when taking Reyataz from the FDA, and is updated regularly.

What is Reyataz?

Reyataz has active ingredients of atazanavir sulfate. It is often used in hiv infection. eHealthMe is studying from 11,386 Reyataz users. Check the latest studies of Reyataz.

What is Alpha 1 foetoprotein abnormal?

Alpha 1 foetoprotein abnormal is found to be associated with 28 drugs and 28 conditions by eHealthMe. Check the latest studies of Alpha 1 foetoprotein abnormal.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

11,228 people reported to have side effects when taking Reyataz.
Among them, 17 people (0.15%) have Alpha 1 foetoprotein abnormal.

Could Reyataz cause Alpha 1 foetoprotein abnormal?

Among these 17 people:

How long have people been on Reyataz when they have Alpha 1 foetoprotein abnormal? *

What is the gender of people who have Alpha 1 foetoprotein abnormal when taking Reyataz? *

female: 73.33 %
male: 26.67 %

What is the age of people who have Alpha 1 foetoprotein abnormal when taking Reyataz? *

What are other drugs people take besides Reyataz? *

What are other side effects people have besides Alpha 1 foetoprotein abnormal? *

Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 5 people, 29.41%
Birth Control: 4 people, 23.53%
Trisomy 18 (a genetic disorder caused by the presence of all or part of an extra 18th chromosome): 3 people, 17.65%
Drug Exposure During Pregnancy: 3 people, 17.65%
Stillbirth (a birth of dead foetus): 1 person, 5.88%
Premature Rupture Of Membranes: 1 person, 5.88%
Maternal Exposure During Pregnancy (use of substance during pregnancy): 1 person, 5.88%
Convulsion Neonatal (muscle contraction and relaxation rapidly in neonate): 1 person, 5.88%

What are the existing conditions these people have? *

Ill-Defined Disorder: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Reyataz and have Alpha 1 foetoprotein abnormal?

- Check whether Alpha 1 foetoprotein abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Reyataz:

Reyataz (11,386 reports)

Browse all side effects of Reyataz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Alpha 1 foetoprotein abnormal:

Alpha 1 foetoprotein abnormal (28 drugs)

Browse all the conditions that are associated with Alpha 1 foetoprotein abnormal:

Alpha 1 foetoprotein abnormal (28 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on atazanavir sulfate (the active ingredients of Reyataz) and Reyataz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.